Anavex Life Sciences Corp (AVXL)

[polarbear77]

I believe that international patent published on 2/1/2018 “A2-73 AS A THERAPEUTIC FOR INSOMNIA, ANXIETY, AND AGITATION” posted by Greenspam yesterday is important for the reasons Jimmy667 outlined.

This very well could be an INTEGRAL component to our ph2/3 confirmatory AD trial and an endpoint related to the new CNS 21st CCA real world evidence precision medicine protocols in 2018.

(As an aside, I’ve not read similar types of quality of life improvement claims from our BP competitors with their CNS and AD drugs; instead I keep reading of unfortunate and lengthy lists of dangerous side effects with their current SOC & clinical trial drugs. I wonder if the FDA will appreciate that apparent dichotomy, if proven out later this year?)

https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=1C394926B1F4E26052A40592F705F07D.wapp2nA?docId=WO2018022848&recNum=1&maxRec=13&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28anavex%29&tab=PCTDescription

I’ll take this opportunity to also list a few of the other reasons I’m currently optimistic about this Company and its MOA and compounds:

Sleep

Prior NIH published studies and Dr George Perry have discussed the links between sleep and restoring cellular homeostasis and reduction of oxidative stress.

Below are a couple of interesting articles regarding this topic:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921176/#!po=1.60550

https://therivardreport.com/utsa-pursues-progress-against-alzheimers-cancer-and-biological-warfare/

Neuro-inflammation (NI)

https://cosmosmagazine.com/biology/brain-inflammation-sows-the-seeds-of-alzheimer-s
“The paper bridges different camps and puts inflammation front and centre as a potential cause of AD,” says Bryce Vissel, an AD researcher at the University of Technology, Sydney.

Anavex says about a2-73:
“The drug candidate has the potential to restore the molecular balance of cells by targeting misfolded proteins and mitochondria dysfunction. This ultimately prevents oxidative stress, inflammation, and cellular stress, processes that are shared by many neurological disorders and known to contribute for nerve cell degeneration.”

Isn’t this a strong clue/benefit of our upstream approach in AD/PD/RS/MS etc? Reduction of inflammation and oxidative stress?

Very encouraging study published regarding 3-71 on 12/29/17 in the Alzheimer’s Association’s journal:

Preclinical AD study conducted in Canada
“
AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer's disease”
http://www.alzheimersanddementia.com/article/S1552-5260(17)33851-7/fulltext

https://www.ncbi.nlm.nih.gov/m/pubmed/29291374/

It’s enough to warrant optimism IMO, although success is not guaranteed as you’re aware. GLTAL